Article Text

PDF
THU0100 In early inflammatory arthritis a lymphoid pathotype signficantly associates with requirement for biologic therapy at 12 months follow up: results from the pathobiology of early arthritis cohort (PEAC)
  1. G Lliso-Ribera1,
  2. F Humby1,
  3. S Kelly1,
  4. M Bombardieri1,
  5. M Lewis1,
  6. R Hands1,
  7. V Rocher1,
  8. F Bene1,
  9. A Nerviani1,
  10. C Buckely2,
  11. P Taylor3,
  12. I McInnes4,
  13. C Pitzalis1
  1. 1Experimental Medicine and Rheumatology, Queen Mary University London, London
  2. 2Centre for Translational Inflammation Research, University of Birmingham, Birmingham
  3. 3Kennedy Institute of Rheumatology, University of Oxford, Oxford
  4. 4Experimental Medicine and Rheumatology, University of Glasgow, Glasgow, United Kingdom

Abstract

Background Early aggressive treatment in RA equates to better long term outcomes, however targeting aggressive therapies including biologics to patients with the worse prognosis is critical to deliver acceptable risk/benefit ratios and health economic improvements. Such an approach requires prognostic biomarkers, whether the well recognised heterogeneity in synovial pathobiology in early RA translates to specific disease outcomes is currently unknown.

Objectives The aim of this study was to investigate whether in a treatment naïve early inflammatory arthritis cohort, baseline synovial pathotype significantly associates with disease outcome at 12 months.

Methods 166 consecutive DMARD naïve patients recruited as part of PEAC at Barts Health NHS Trust with synovial tissue suitable for analysis were included. At baseline patients were classified as RA (2010 ACR/EULAR criteria) or undifferentiated (UA). All patients underwent a baseline synovial biopsy of a clinically active joint along with collection of demographic data. Patients were subsequently treated with DMARD +/- steroid therapy with aim for low disease activity (DAS <3.3). At 6 month follow up patients were escalated to biologic therapy if fulfilling UK NICE guidelines. At 12 months patients were classified as: (i) no treatment, (ii) DMARDs, and (iii) Biologic +/- DMARDs. Sequentially cut sections of baseline synovial biopsies underwent immunohistochemical staining and semi-quantitative scoring (0–4) to determine the degree of CD20+Bcells, CD3+T cells, CD68+ lining (l) and sublining (sl) macrophage and CD138+ plasma cell infiltration. Sections were categorised into 3 pathotypes, (i) Fibroid: (CD68 SL<2 and or CD3, CD20, CD138<1), (ii) Myeloid: (CD68SL>2, CD20<1 and or CD3>1) and (iii) Lymphoid: (grade 2–3 CD20+ aggregates, CD20>2).

Results 79% were classified as RA and 21% as UA. Mean disease duration was 9.27 months. 92% (153/166) patients had follow-up at 12months. 29% (44/153) of patients were classified as fibroid, 34% (52/166) as myeloid and 37% (57/166) as lymphoid. At baseline patients with a lymphoid pathotype had a significantly higher CRP and DAS28 and were significantly more likely to be sero positive for for RF and ACPA (p<0.05), suggesting that a lymphoid pathotype is associated with higher levels of disease activity. At 12 months follow up a significantly higher proportion of patients classified as lymphoid vs myeloid or fibroid (58% vs 21% vs 21%) required biologic therapy.

Conclusions Results demonstrate that in an early inflammatory arthritis cohort a lymphoid pathotype significantly associates with higher disease activity at baseline, sero positivity for RF and ACPA and a requirement for more aggressive therapy at 12 month. This supports a direct role for synovial lymphoid structures in disease pathogenesis and suggests a role as a prognostic biomarker facilitating early stratification of aggressive therapeutic intervention.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.